Real-world use of multiplex point-of-care molecular testing or laboratory-based molecular testing for influenza-like illness in a 2021 to 2022 US outpatient sample.
While molecular testing is recommended for symptomatic patients suspected of having coronavirus disease 2019 (COVID-19), limited data are available examining real-world use of tests for severe acute respiratory syndrome coronavirus (SARS-CoV-2) and the impact of SARS-CoV-2 testing on patient outcome...
| 發表在: | PLoS ONE |
|---|---|
| Main Authors: | , , , , , |
| 格式: | Article |
| 語言: | 英语 |
| 出版: |
Public Library of Science (PLoS)
2024-01-01
|
| 在線閱讀: | https://doi.org/10.1371/journal.pone.0313660 |